CC
CNTX icon

Caxton Corporation’s Context Therapeutics CNTX Stock Holding History

Caxton Corporation’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,403
Closed -$27.1K – 9
2025
Q4 		$27.1K Hold
18,403
– – 0.63% 11
2025
Q3 		$17.8K Hold
18,403
– – 0.08% 12
2025
Q2 		$12.1K Hold
18,403
– – 0.12% 11
2025
Q1 		$11.3K Hold
18,403
– – 0.22% 12
2024
Q4 		$19.3K Hold
18,403
– – 0.12% 14
2024
Q3 		$36.1K Hold
18,403
– – 0.15% 11
2024
Q2 		$36.9K Buy
+18,403
New +$31.7K 0.19% 11

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Caxton Corporation's CNTX Position: Q1 2026 in Review

Caxton Corporation sold out of Context Therapeutics (CNTX) in Q1 2026, closing a stake of 18,403 shares — an estimated $27.1K sold.

Caxton Corporation first reported a position in CNTX in Q2 2024 and held it in 7 quarters. The position peaked at $36.9K in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Caxton Corporation reported no remaining Context Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caxton Corporation sold 18,403 Context Therapeutics shares in Q1 2026, an estimated $27.1K.
  • Caxton Corporation first reported a position in Context Therapeutics in Q2 2024 and held it in 7 quarters.
  • Caxton Corporation's Context Therapeutics position peaked at $36.9K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Caxton Corporation's 13F filing for Q1 2026, filed 14 May 2026.